AbilityPharma

About AbilityPharma

AbilityPharma is a clinical stage phase 2b biopharmaceutical company based in Cerdanyola del Vallès, Barcelona, Catalonia, Spain, focused on developing first-in-class cancer treatments using autophagy as a novel therapeutic strategy to induce selective cell death in cancer cells.

Products & Services

ABTL0812 (IBRILATAZAR):A first-in-class cancer treatment currently in phase 2b clinical trials for metastatic pancreatic cancer in the USA, Spain, France, and Israel. It has also completed phase 2a trials with positive results for endometrial and lung cancer in Spain and France.

Specialties

Autophagy-based cancer treatments First-in-class cancer drug development Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Round T: - FT: Venture Round	A: 7560000 MR: - FA: €7 Million FAN: 7560000	D: 2024-03-11 FD: 2024-03-11	7 investors
2	RT: Venture Round T: - FT: Venture Round	A: 7595000 MR: - FA: €7 Million FAN: 7595000	D: 2024-03-11 FD: 2024-03-11	5 investors

Venture Round Latest

2024-03-11

$7.6M

7 investors (Pro only)

Venture Round 2024-03-11

$7.6M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

José Miguel Lizcano

Chairman, Scientific Advisory Board

P

Pere Gascón

Senior Consultant in Medical Oncology

J

Jordi Rodón

Specialist in Medical Oncology

M

Miguel F. Segura

Principal Investigator

S

Soledad Gallego

Pediatric Oncologist, Professor of Pediatrics, and Head of Pediatric Oncology and Hematology Service

A

Antoni Martinez-Tobed

View 31 more team members with Pro

Unlock Full Team Directory

Recent News

AbilityPharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised